FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2019/06/019634 [Registered on: 12/06/2019] Trial Registered Prospectively
Last Modified On: 13/10/2020
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Biological 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   Study in Patients with surgically removable Non-Small Cell Lung Cancer (NSCLC) with Durvalumab plus Chemotherapy before and after surgical removal of tumour versus surgical removal of tumour alone with chemotherapy 
Scientific Title of Study   A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) 
Trial Acronym   
Secondary IDs if Any
Modification(s)  
Secondary ID  Identifier 
D9106C00001 Version 3.0, dated 26 Nov 2019  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name   
Designation   
Affiliation   
Address 




 
Phone    
Fax    
Email    
 
Details of Contact Person
Scientific Query
 
Name  Mr Tapankumar M Shah 
Designation  Country Director, Clinical Operations 
Affiliation  AstraZeneca Pharma India Limited 
Address  AstraZeneca Pharma India Ltd. Block N1, 12th Floor, Manyata Embassy Business Park Rachenahalli, Outer Ring Road

Bangalore
KARNATAKA
560045
India 
Phone  91-9535104975   
Fax  91-8067748857   
Email  tapankumar.shah@astrazeneca.com  
 
Details of Contact Person
Public Query
 
Name  Mr Tapankumar M Shah 
Designation  Country Director, Clinical Operations 
Affiliation  AstraZeneca Pharma India Ltd. 
Address  AstraZeneca Pharma India Ltd. Block N1, 12th Floor, Manyata Embassy Business Park Rachenahalli, Outer Ring Road

Bangalore
KARNATAKA
560045
India 
Phone  91-9535104975   
Fax  91-8067748857   
Email  tapankumar.shah@astrazeneca.com  
 
Source of Monetary or Material Support  
AstraZeneca AB, 151 85 Sodertalje Sweden 
 
Primary Sponsor  
Name  AstraZeneca AB  
Address  151 85 Sodertalje Sweden  
Type of Sponsor  Pharmaceutical industry-Global 
 
Details of Secondary Sponsor  
Name  Address 
AstraZeneca Pharma India Ltd  Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore – 560045, India  
 
Countries of Recruitment     Argentina
Austria
Chile
Hungary
India
Japan
Mexico
Republic of Korea
Russian Federation
Taiwan
Thailand
Ukraine
United States of America
Viet Nam  
Sites of Study
Modification(s)  
No of Sites = 16  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Samit Purohit  Action Cancer Hospital  Dept. of Medical Oncology Consultant Medical Oncologist A4, Paschim Vihar, New Delhi-110063, India
New Delhi
DELHI 
01149222222
01145024287
samitmedonc@gmail.com 
Dr Vineet Govinda Gupta  Artemis Hospital  Dept. of Medical Oncology Consultant Medical Oncology, Medical Oncologist Sector 51, Gurgaon PIN 122001
Gurgaon
HARYANA 
9911152107
01246767701
vineet.gupta@artemishospitals.com 
Dr Nirmal Vivek Raut  Bhaktivedanta Hospital & Research Institute  Dept. of Medical Oncology Srishti complex, Bhaktivedanta Swami Marg, Mira Road (East), PIN– 401107
Thane
MAHARASHTRA 
9930398156

drnirmalraut@gmail.com 
Dr Ashish Kaushal  HCG Cancer Centre  Dept. of Medical Oncology Consultant Medical Oncologist Sola-Science City Road, Near Sola Bridge, S.G. Highway, Ahmedabad - 380060
Ahmadabad
GUJARAT 
07940410101

drashish4@yahoo.co.in 
Dr Shruti Kate  HCG Manavata Cancer Centre  Dept. of Medical Oncologist Senior Consultant Medical Oncologist Behind Shivang Auto, Mumbai Naka, Nasik - 422002, Maharashtra India
Mumbai
MAHARASHTRA 
02536661111

drshruti@mcrinasik.com 
Dr Dipanjan Panda  Indraprastha Apollo Hospitals Delhi  Dept. of Medical Oncology Mathura Road, Sarita Vihar PIN- 110076
New Delhi
DELHI 
9540946934

dipanjan.panda@gmail.com 
Dr Sewanti Lemaye  Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute  Dept. of Medical Oncology Consultant Medical Oncologist Rao Saheb, Achutrao Patwardhan Marg, Four Bungalows, Andheri West, Mumbai India
Mumbai
MAHARASHTRA 
02230999999

sewanti.limaye@relianceada.com 
Dr Praveena Voonna  Mahatma Gandhi Cancer Hospital and Research Institute,  Consultant Medical Oncologist Dept. of Medical Oncology 1/7 MVP Colony, Vishakhapatnam PIN 530017 India
Visakhapatnam
ANDHRA PRADESH 
08912878787
08912506103
praveena.voonna@gmail.com 
Dr Vaibhav Choudhary  Meditrina Institute of Medical Sciences  Dept. of Medical Oncilogy Consultant Medical Oncologist 278.Central Bazar Road, Ramdaspeth, Nagpur-440010 India
Nagpur
MAHARASHTRA 
9833621049

dr.vaibhav155@gmail.com 
Dr Krishnakumar Rathnam  Meenakshi Mission Hospital & Research Institute  Dept. of Medical Oncology Meenakshi Mission Hospital and Research Centre Lake Area, Melur Road. PIN - 625107
Madurai
TAMIL NADU 
9380417299

kkrathnam@gmail.com 
Dr Minish Jain  Noble Hospital Pvt. Ltd  Dept. of Medical Oncology Consultant Medical Oncologist 153, Magarpatta City Road, Pune - 411013, Maharashtra, India
Pune
MAHARASHTRA 
02066285000
02066285199
minishjain009@rediffmail.com 
Dr Rangarao Rangaraju  Paras Hospital  Dept. of Medical Oncology C-1 , Sushant Lok-1 Sector-43 Gurugram PIN- 122001
Gurgaon
HARYANA 
09810297787

rangaraorr@gmail.com 
Dr Chandan K Das  Post Graduate Institute of Medical Education & Research  Dept. of Medical Oncology, PGIMER Chandigarh, Department of Radiotherapy and Oncology, Regional Cancer Centre, Sector 12, Chandigarh‐ 160012
Chandigarh
CHANDIGARH 
07087003410

ckdasoncology@gmail.com 
Dr Ullas Batra  Rajiv Gandhi Cancer Institute and Research Centre  Senior Consultant and Unit Head, Chief of Thoracic Medical Oncologist Room no. 2251, Department of Medical Oncology, Sector 5 Rohini, Delhi 110085 India
New Delhi
DELHI 
01147022222
01147022222
ullasbatra@gmail.com 
Dr Bivas Biswas   Tata Medical Center  Consultant Medical Oncologist Department of Medical Oncology, Tata Medical Center, 14 Major Arterial Road (EW), Newtown, Rajarhat, Kolkata, India- 700 160, India
Kolkata
WEST BENGAL 
913366057000
913366057635
bivas.biswas@tmckolkata.com 
Dr Deepan Rajamanickam  Thangam Hospital and Thangam Cancer Center  Dept. of Medical Oncology No.54, Dr. Sankaran Road, PIN – 637001.
Namakkal
TAMIL NADU 
9619163678

deepan_rm@yahoo.co.in 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 16  
Name of Committee  Approval Status 
Action Cancer Hospital Ethics Committee  Approved 
Artemis Health Sciences Institutional Ethics Committee  Approved 
Bhaktivedanta Hospital Ethics Committee  Approved 
HCG Multi Specialty Ethics Committee, Ahmedabad   Approved 
Institutional Ethics Committee, PGIMER  Approved 
Institutional Ethics Committee- Clinical Studies, Apollo, Sarita Vihar, Delhi  Approved 
Institutional Review Board Rajiv Gandhi Cancer Institute and Research Centre  Approved 
Institutional Review Board Tata Medical Center, Kolkata  Approved 
Kokilaben Dhirubhai Ambani Hospital and Medical Research Institutional Ethics Committee  Approved 
Mahatma Gandhi Cancer Hospital and Research Institute Institutional Review Board, Vishakhapatnam  Approved 
Manavata Clinical Research Institute Ethics Committee  Approved 
Meditrina Institute Ethics Committee  Approved 
Meenakshi Mission Hospital and Research Centre (MMHRC) INSTITUTIONAL ETHICS COMMITTEE   Approved 
Noble Hospital Pvt. Ltd Institutional Ethics Committee  Approved 
Paras Hospital Ethics Committee   Approved 
Thangam Hospital - INSTITUTIONAL ETHICS COMMITTEE   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Approved/Obtained 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  C349||Malignant neoplasm of unspecifiedpart of bronchus or lung,  
 
Intervention / Comparator Agent
Modification(s)  
Type  Name  Details 
Intervention  Durvalumab   Durvalumab plus Comparator Agent Placebo plus Chemotherapy 
Comparator Agent  Placebo plus Chemotherapy  Durvalumab plus Comparator Agent Placebo plus Chemotherapy 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  Informed consent
1.Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

2. Provision of signed and dated written ICF prior to any mandatory study specific procedures, sampling, and analyses.

3. Provision of signed and dated written ICF prior to collection of sample for genetic analysis.
Age

4. Age ≥18 years at the time of screening. For patients aged <20 years and enrolled in Japan, a written informed consent should be obtained from the patient and his or her legally acceptable representative.
Type of patient and disease characteristics

5. Histologically or cytologically documented NSCLC with resectable (Stage IIA to select [ie, N2] Stage IIIB) disease (according to Version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology).

i).At screening, complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a multidisciplinary evaluation, which must include a thoracic surgeon who performs lung cancer surgery as a prominent part of his/her practice.
ii).Nodal status should be investigated with whole body 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET), plus contrast-enhanced computed tomography (CT) in addition to or in combination with PET before surgery. If PET/CT scan is positive in the mediastinum, or if scan is negative but there is T>3 cm, central tumor, or clinical N1 (cN1), then nodal status should be proven by biopsy via endobronchial ultrasound, mediastinoscopy, or thoracoscopy. (preoperative mediastinal lymph node staging).
iii).Mandatory brain magnetic resonance imaging (MRI; preferred) with IV contrast or brain CT with IV contrast at the time of staging.

6. World Health Organization (WHO)/ECOG PS of 0 or 1 at enrolment.

7. At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion (TL) at baseline. Tumor assessment by CT or MRI scan must be performed within 28 days prior to randomization.

8. No prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines.

9. Adequate organ and marrow function as defined below:

i).Hemoglobin ≥9.0 g/dL
ii).Absolute neutrophil count ≥1.5 × 109/L
iii).Platelet count ≥100 × 109/L
iv).Serum bilirubin ≤1.5 × the upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert’s syndrome, who will be allowed in consultation with their physician.
v).ALT and AST ≤2.5 × ULN
vi).Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL >40 mL/min as determined by Cockcroft-Gault (using actual body WT)
Males:
Creatinine CL is equal to WT (kg) × (140-Age) (mL/min) 72 × serum creatinine (mg/dL)
Females:
Creatinine CL is equal to WT (kg) × (140-Age) × 0.85(mL/min) 72 × serum creatinine (mg/dL)

10. Must have a life expectancy of at least 12 weeks.

11. Body WT >30 kg.

Sex

12. Male and/or female.

Tumor sample requirements:

13. Confirmation of a patient’s tumor PD-L1 status must occur prior to randomization using Ventana PD-L1 (SP263) immunohistochemistry (IHC) assay applied to formalin fixed paraffin embedded tissue sample with testing completed by the central laboratory.

Samples for PD-L1 testing may include the following:
i).Newly acquired tumor tissue (preferred) or archival tissue (<3 months old).
ii).If the patient’s PD-L1 status has already been assessed using the analytically validated Ventana assay as a part of the screening process for another AstraZeneca/MedImmune study, this test result can be used for the determination of eligibility.

14. Documented EGFR and ALK status (local testing is preferred; if not feasible, central testing will be performed). If the local laboratory will perform the test, a well-validated, local regulatory-approved kit must be used. EGFR/ALK status should be available prior to randomization. If the number of patients with EGFR or ALK mutations (ie, the total number of patients summed across both types of mutations) reaches approximately 20% of the total randomization target patient number, the incoming patients with EGFR/ALK
mutations will not be randomized.
Surgery eligibility (these criteria must be assessed within 30 days prior to surgery, following neoadjuvant treatment)

15. Surgery to be performed will be lobectomy, sleeve resection, bilobectomy, or pneumonectomy, as determined by the attending surgeon based on the intraoperative findings.

16. Received 4 cycles of platinum-based chemotherapy concurrent with durvalumab or placebo
i).Receipt of 3 cycles of platinum-based chemotherapy concurrent with durvalumab or placebo will be permitted only if the patient experienced chemotherapy related toxicities and Investigators judge additional safety issue will be expected with additional cycles of chemotherapy.

17. Surgery should happen within 40 days from the last IP administration.

18. Patients must have recovered from all acute, reversible toxic effects from chemotherapy (excluding alopecia) and durvalumab or placebo that could potentially adversely impact the surgical procedure or outcome according to the Investigator’s judgement.

19. A contrast enhanced CT/MRI scan of chest and abdomen (including the entire liver and both adrenals) are required for RECIST 1.1 assessment and for surgical planning prior to surgery. A supplemental (whole body) FDG-PET scan may also be acquired prior to surgery in order to help identify mediastinal lymph node involvement, according to investigators judgement.

20. If preoperative CT and/or PET are suspicious for mediastinal nodal involvement, or should those be negative for mediastinal lymph node but there is T>3 cm, cN1, or central tumor, then it is recommended that invasive mediastinal staging with thoracoscopy or mediastinoscopy or endobronchial ultrasound-guided transbronchial needle aspiration be performed if those were not performed at screening and/or according to the multidisciplinary evaluation and Investigator’s judgment.

21. Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a multidisciplinary evaluation, which must include a thoracic surgeon who perform lung cancer surgery as a prominent part of his/her practice.

22. Deemed adequate cardiac and lung function, according to the multidisciplinary assessment. A pre- or post-bronchodilator forced expiratory volume in 1 second (FEV1) of 1.0 L or >40% postoperative predicted value and diffusing capacity of the lungs for carbon monoxide (DLCO) >40% predicted value is recommended.

Post-surgery durvalumab or placebo administration eligibility (these criteria must be assessed within 10 weeks from surgery, prior to starting adjuvant treatment)

23. Patients must have recovered from all acute, reversible toxic effects from previous treatments that could potentially adversely impact further administration of durvalumab or placebo according to the Investigator’s judgement.

24. Patients should be able to start durvalumab or placebo administration as soon as clinically feasible and within 10 weeks from surgery. A minimum of 3 weeks is recommended between NSCLC surgery and durvalumab/placebo treatment start (first post-surgical scan must be performed prior to starting adjuvant treatment). Complete post-operative wound healing must have occurred following any surgery.

25. Patients with N2 disease or patients with R1/2 post-surgical findings can receive adjuvant post-operative radiation therapy (within 8 weeks after surgery) and are eligible to receive post-surgery durvalumab/placebo (within 3 weeks from end of post-operative radiation therapy). The post-operative radiation therapy must be completed prior to durvalumab/placebo administration.
 
 
ExclusionCriteria 
Details  Medical conditions

1. History of allogeneic organ transplantation.

2. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn’s disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [eg, granulomatosis with polyangiitis, Graves’ disease, rheumatoid
arthritis, hypophysitis, or uveitis]).

The following are exceptions to this criterion:
i).Patients with vitiligo or alopecia.
ii).Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on
iii).hormone replacement.
iv).Any chronic skin condition that does not require systemic therapy.
v).Patients without active disease in the last 5 years may be included but only after consultation with the Study Physician
vi).Patients with celiac disease controlled by diet alone.

3. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active ILD, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent.

4. History of another primary malignancy, except for the following:
i).Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence
ii).Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
iii).Adequately treated carcinoma in situ without evidence of disease

5. History of active primary immunodeficiency

6. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (known positive hepatitis B virus surface antigen [HBsAg] result), hepatitis C virus (HCV), or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved hepatitis B virus (HBV) infection (defined as the presence of hepatitis B core antibody and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).

7. Deemed unresectable NSCLC by multidisciplinary evaluation that must include a thoracic surgeon who perform lung cancer surgery as a significant part of their practice

8. Patients who have pre operative radiotherapy treatment as part of their care plan

9 Patients who have brain metastases or spinal cord compression. All patients will have an MRI (preferred) or high quality CT with IV contrast of the brain, prior to study entry.

10. Stage IIIB N3 and Stages IIIC, IVA, and IVB NSCLC

11. Mean QT interval corrected for heart rate using Fridericias formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart).

12. Mixed small cell and NSCLC histology.

13. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

14. Any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the local labelling

15. Patients who are candidates to undergo only segmentectomies or wedge resections.

Prior/concomitant therapy

16. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.
Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable.

17. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.

18. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.

19. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP

20. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
i) Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)
ii) Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
iii) Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)

Prior/concurrent clinical study experience
21. Participation in another clinical study with an IP administered in the last 4 weeks.

22. Previous IP assignment in the present study.

23. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study

24. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.

Diagnostic assessments
Other exclusions

25. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of IP.

26. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.

27. Exclusion criteria for participation in the optional (DNA) genetics research component of the study include the following:
i). Previous allogeneic bone marrow transplant
ii). Non-leukocyte-depleted whole blood transfusion in 120 days of genetic sample collection post-menopausal. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
iii). Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution.
iv). Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, or had chemotherapy-induced menopause with last menses >1 year ago.
v). Women who are surgically sterile (ie, bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) are eligible.
 
 
Method of Generating Random Sequence   Stratified block randomization 
Method of Concealment   Centralized 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome
Modification(s)  
Outcome  TimePoints 
To compare the efficacy of durvalumab +chemotherapy administered prior to surgery followed
by durvalumab post-surgery compared with placebo+ chemotherapy administered prior to surgery
followed by placebo post-surgery in terms of EFS
To assess the activity of durvalumab + chemotherapy administered prior to surgery compared with placebo+ chemotherapy administered prior to surgery in terms of mPR 
EFS

mPR (10% or less residual viable tumor tissue in lung primary tumor after neoadjuvant treatment at the time of resection) 
 
Secondary Outcome
Modification(s)  
Outcome  TimePoints 
1.To compare the efficacy of durvalumab PLUS chemotherapy administered prior to surgery followed by durvalumab post-surgery compared with placebo PLUS chemotherapy administered Prior to surgery followed by placebo post-surgery in Terms of DFS
 
DFS 
2. To compare the activity of durvalumab PLUS chemotherapy administered prior to surgery compared with placebo PLUS Chemotherapy administered prior to surgery in terms of pCR   pCR (absence of any residual viable tumor in the primary lung lesion and lymph nodes at the time of surgical resection) 
3.To compare the efficacy of durvalumab PLUS chemotherapy administered prior to surgery followed by durvalumab post-surgery compared with placebo PLUS chemotherapy administered prior to surgery followed by placebo post-surgery in terms of OS   OS 
4.To compare the efficacy of durvalumab PLUS chemotherapy administered prior to surgery followed by durvalumab post-surgery compared with placebo PLUS chemotherapy administered prior to surgery followed by placebo post-surgery in patients with PD-L1-TC≥1% in terms of EFS, mPR, DFS, and pCR
 
EFS
mPR
DFS
pCR
 
5.To compare disease-related symptoms and HRQoL in patients treated with durvalumab PLUS chemotherapy administered prior to surgery followed by durvalumab post-surgery compared with placebo PLUS chemotherapy administered prior to surgery followed by placebo post-surgery  Change from baseline and time to deterioration in EORTC QLQ-C30 and EORTC QLQ-LC13 
6.To assess the PK of durvalumab ∙ Concentration of durvalumab   Concentration of durvalumab 
7.To investigate the immunogenicity of durvalumab   Presence of ADAs for durvalumab 
Safety objective:

1.To assess the safety and tolerability profile of durvalumab PLUS chemotherapy administered prior to surgery followed by durvalumab post-surgery compared with placebo PLUS chemotherapy administered prior to surgery followed by placebo post-surgery
∙ AEs, physical examinations, vital signs (including BP, pulse, and ECGs), and laboratory findings (including clinical chemistry, hematology, and urinalysis)
 
AEs, physical examinations, vital signs (including BP, pulse, and ECGs), and laboratory findings (including clinical chemistry, hematology, and urinalysis) 
Exploratory objectives:
1.To investigate the effect on ctDNA, tumor protein, and/or blood RNA-based biomarkers in patients treated with durvalumab PLUS chemotherapy administered prior to surgery followed by durvalumab post-surgery compared with placebo PLUS chemotherapy administered prior to surgery followed by placebo post-surgery, and associations with clinical endpoints
 
ctDNA: Evaluations including, but not limited to, baseline mutations, changes in levels on-treatment prior to and following surgery, and blood TMB at baseline
IHC: Including, but not limited to, PD-L1 and/or CD8 protein expression at baseline and following surgery
Blood mRNA expression: Including, but not limited to, immune-relevant gene signatures at baseline
 
To compare the activity of durvalumab PLUS chemotherapy administered prior to surgery compared with placebo PLUS chemotherapy administered prior to surgery in terms of mPR assessed according to the immune related pathologic response criteria (Cottrell et al 2018)  mPR (10% or less residual viable tumor tissue in lung primary tumor after neoadjuvant treatment at the time of resection) in FAS 
To explore the impact of treatment and disease on health state utility
To explore the impact of treatment and disease on health care resource use
 
EQ-5D-5L, descriptor, and VAS
Health care resource use will be captured, including inpatient admissions, ICU admissions, and length of stay in the hospital. Study-mandated visits are excluded from this assessment.
 
To investigate the effect of baseline colonic microbiome on response to treatment and the effect of treatment on the microbiome over time  Microbiome culture, analysis, and metabolome analysis of stool sample 
To assess treatment-related symptoms using PRO CTCAE
To assess the patient’s overall impression of the severity of their cancer symptoms using PGIS
 
Change in specific treatment-related symptoms
Proportion of patients assessing current symptom severity
 
 
Target Sample Size   Total Sample Size="300"
Sample Size from India="40" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   17/06/2019 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  06/12/2018 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="5"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Open to Recruitment 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   Not yet 
Brief Summary
Modification(s)  

This is a Phase III, double-blind, placebo-controlled, multi-center international study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable Stages II and III NSCLC.

 

Approximately 800 patients with resectable NSCLC (Stage IIA to select Stage IIIB; either squamous or non-squamous) will be randomized in a 1:1 ratio to receive either durvalumab plus platinum-based chemotherapy before surgery followed by durvalumab post-surgery or placebo plus platinum-based chemotherapy before surgery followed by placebo post-surgery.

 

Patients will be stratified by disease stage (Stage II versus Stage III) and by PD-L1 expression status (<1% versus ≥1%). The percentage of patients with EGFR/ALK mutations will be capped at approximately 20% of the patients randomized. Once the cap is reached, EGFR/ALK mutated patients will no longer be allowed to enter the study.

 

Patients will receive 4 cycles of durvalumab or placebo plus platinum-based chemotherapy (q3w) followed by surgery. Surgery may consist of lobectomy, sleeve resection, bilobectomy, or pneumonectomy as determined by the attending surgeon based on the intraoperative findings. Patients who are candidates to undergo only segmentectomies or wedge resections at eligibility assessment are not eligible for this study.

All patients must be staged and managed according to the National Comprehensive Cancer Network 2018 Guidelines (version 4).

An early safety evaluation by an IDMC will review the data from the first 40 patients across both treatment arms who have undergone surgery and had 21 days of follow-up, in order to assess perioperative mortality and surgery delays. Surgery is expected within 40 days from the last IP dose. The IDMC will then meet regularly at 6-month intervals to review the safety and tolerability of durvalumab plus chemotherapy as neoadjuvant regimen and of durvalumab post-surgery, until all patients across both treatment arms have undergone surgery and have had at least 6 months of follow-up. Safety reviews will be carried out by the IDMC in an unblinded manner. The IDMC will report back to the Sponsor with any recommendations regarding modifications to the study.

 

Patients should be able to start durvalumab or placebo administration following surgery as soon as clinically feasible and within 10 weeks from surgery (except for patients receiving post-operative radiation therapy, which must be started within 8 weeks after surgery; durvalumab/placebo must be given within 3 weeks from the end of post-operative radiation therapy). Patients randomized to receive durvalumab plus platinum-based chemotherapy prior to surgery will receive an additional 12 cycles of durvalumab 1500 mg q4w, while patients randomized to receive placebo plus platinum-based chemotherapy prior to surgery will receive an additional 12 cycles of placebo q4w.

 

Tumor evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to randomization); after the completion of neoadjuvant chemotherapy prior to surgery; every 12 weeks (q12w)±1 week (relative to the date of surgery) for the first year; every 24 weeks (q24w)±1 week (relative to the date of surgery) for years 2, 3, and 4; and then yearly (relative to the date of surgery) thereafter, until RECIST 1.1-defined radiological PD, consent withdrawal, or death. For patients who do not have surgery and therefore will not have a first post-surgical scan or adjuvant treatment, scans will be conducted q12w±1 week (relative to the date of the planned pre-surgery scan) for the first year; q24w±1 week (relative to the date of the pre-planned surgery) for years 2, 3, and 4; and then yearly (relative to the date of the pre-planned surgery) thereafter, until RECIST 1.1-defined radiological PD, consent withdrawal, or death.


 
Close